Global Cytokine Release Syndrome Drug Market – Industry Trends and Forecast to 2030

Cytokine Release Syndrome Drug Market Analysis and Size

A rise in the government initiatives to accelerate research and development of novel therapies for the treatment of cytokine release syndrome (CRS) will uplift the market growth, also increase in awareness about treatment and technological advancement, rise in the prevalence of the disease, and increase in the healthcare expenditures all over the globe are some of the crucial factors among others, driving the cytokine release syndrome drug market. Moreover, the rise in technological advancement and modernization in the healthcare devices used and the increase in the demand from emerging economies will further create new opportunities for the cytokine release syndrome drug market in the forecast period.

Data Bridge Market Research analyses that the cytokine release syndrome drug market which was USD 22.32 billion in 2022, would rocket up to USD 35.27 billion by 2030, and is expected to undergo a CAGR of 6.10% during the forecast period. “Hospitals” dominates the end user segment of the cytokine release syndrome drug market owing to the growing demand for the drug. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Cytokine Release Syndrome Drug Market Scope and Segmentation

Market Definition

Cytokine release syndrome is defined as a condition caused by the rapid release of cytokines from the immune cells into the bloodstream. Cytokine release syndrome occurs after the treatment of immunotherapies such as monoclonal antibodies and CAR-T cells. People may experience high fever, nausea, headache, hypotension, rash, rapid heartbeat, low blood pressure, and difficulty breathing.

Global Cytokine Release Syndrome Drug Market Dynamics

Drivers

• Increasing prevalence of cancer

This is attributable to the increased adoption of immunotherapy for the treatment of cancer across the globe. People are now increasingly adopting targeted therapy and immunotherapy as they are more convenient, practical and have low side-effects compared to traditional chemotherapy. The low toxicity and the ability of the targeted therapy to specifically target the cancer cells without harming the normal cells is boosting the market's growth significantly. For instance, as per the Globocan 2020, the number of new cancer cases reported was 19,292,789. This count is expected to rise to 28,887,940 by 2040.

•  Rising number of geriatric population

Expanding geriatric population worldwide is predicted to favour cytokine release syndrome drug demand as this population is more prone to chronic diseases. The number of persons above 65 years is projected to double in the coming years. The old age people are prone to various chronic diseases which can foster the demand for cytokine release syndrome drug across the globe.

According to the United Nations, there were around 382 million old age people aged 60 years or above, across the globe in 2017, and this number is expected to be 2.1 billion by 2050.

• Advancement of therapies for the treatment

Advancement of therapies for the treatment is the expected factors that will increase the growth of the cytokine release syndrome drug market. Cytokine release syndrome (CRS) is a systemic inflammatory response that can be triggered by a variety of factors such as infections and certain drugs causing pathologic over-activation of T cells, leading to hypersecretion of cytokines by T cells and other immune cell types.

Moreover, it is anticipated that the market for cytokine release syndrome drug will exhibit lucrative growth, as the symptoms of CRS typically occur within 30–120 min after the infusion has been initiated. Typically, the risk is greater during the first infusion. After CAR T-cell therapy, the onset of CRS symptoms seems to be dependent on the administered dose of the active agent of the proliferation kinetics of adoptively transferred cells and ranges from a few minutes up to 14 days but usually occurs within the first week.

Opportunity

Furthermore, increasing government funds and support for target research activities, rising clinical trials, and rising product innovations and development owing to technological advancements worldwide will extend profitable opportunities for the market players in the forecast period of 2023 to 2030. The demand for specialized treatment is projected to drive the cytokine release syndrome drug market growth. These developments are anticipated to expedite the market expansion for cytokine release syndrome drugs in the future. 

Restraints/Challenges

On the other hand, effective treatment is either unavailable or unaffordable, and insufficient awareness about cytokine release syndrome treatment in some developing countries are the major factors among others that are expected to obstruct market growth. Moreover, patent expiry from many companies and the introduction of generic drugs will further challenge the cytokine release syndrome drug market in the forecast period f 2023-2030.

This cytokine release syndrome drug market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cytokine release syndrome drug market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In April 2022, Sonnet Bio Therapeutics Holdings, Inc., a clinical-stage company developing targeted immunotherapeutic drugs, published their data from preclinical studies of the company's proprietary Fully-Human Albumin Binding candidates, SON-1010, SON-1210, and SON-1410, in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2022. 

Global Cytokine Release Syndrome Drug Market Scope

The cytokine release syndrome drug market is segmented on the basis of cytokine type, therapeutic application, biomarker type, route of administration, and end-user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Cytokine Type

• Tumour Necrosis Factor-TNF
• Interleukins-Il
• Interferons-IFN
• Epidermal Growth Factor-EGF

Therapeutic Application

• Cancer
• Asthma and Airway Inflammation
• Arthritis
• Others

Biomarker Type

• Interleukin-10
• Interferon gamma
• Interleukin-6
• Ferritin and Cluster of Differentiation-163

Route of Administration

• Oral
• Intravenously

End-User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Global Cytokine Release Syndrome Drug Market Regional Analysis/Insights

The cytokine release syndrome drug market is analyzed and market size insights and trends are provided by country, cytokine type, therapeutic application, biomarker type, route of administration and end-user, as referenced above.

The countries covered in the cytokine release syndrome drug market  report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.   

North America dominates the cytokine release syndrome drug market due to increased awareness about treatment and technological advancement, the disease's prevalence, and the healthcare expenditures in this region.

Asia-Pacific is expected to grow at the highest growth rate during the forecast period of 2023 to 2030 due to an increase in the acceptance for immunotherapy for treating solid tumours in this region.

The country section of the report also provides individual market-impacting factors and domestic regulation changes that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The cytokine release syndrome drug market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for the cytokine release syndrome drug market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the cytokine release syndrome drug market. The data is available for the historic period 2010-2021.

Competitive Landscape and Cytokine Release Syndrome Drug Market Share Analysis

The cytokine release syndrome drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the companies' focus related to cytokine release syndrome drug market.

Some of the major players operating in the cytokine release syndrome drug market are:

• F. Hoffmann-La Roche Ltd (Switzerland)
• GlaxoSmithKline Plc (U.K.)
• Novartis AG(Switzerland)
• Sanofi S.A (France)
• Pfizer Inc. (U.S.)
• Bayer AG (Germany)
• AbbVie Inc. (U.S.)
• Johnson & Johnson Private Limited (U.S.)
• Abcam plc (U.K.)
• Amgen Inc.(U.S.)
• Applied Biological Materials Inc.(Canada)
• Bio-Techne Corporation (U.S.)
• GenScript Biotech Corporation (U.S.)
• Randox Laboratories Ltd. (U.K.)
• Thermo Fisher Scientific Inc. (U.S.)

SKU-44740